Metastatic breast cancer Trials in Barcelona, Spain
Conditions / Metastatic breast cancer / Barcelona, Spain
Metastatic breast cancer has been the subject of sustained clinical investigation across multiple research sites.
80 total trials for this combination
Showing top 10 of 80 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04188548 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06324357 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | RECRUITING | — |
| NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | RECRUITING | PHASE1/PHASE2 |
| NCT07085767 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | RECRUITING | — |
| NCT01881230 | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) | COMPLETED | PHASE2/PHASE3 |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | RECRUITING | PHASE3 |
| NCT06324357 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | RECRUITING | — |
| NCT05216432 | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | RECRUITING | PHASE1 |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | RECRUITING | PHASE3 |
| NCT07085767 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | RECRUITING | — |